Avience Biomedicals SME IPO GMP Updates Today: Key Insights on Pricing and Market Sentiment

Avience Biomedicals is set to make its debut in the Indian IPO market with its SME IPO scheduled to open for subscription on June 18, 2026. The public issue aims to raise approximately ₹30.24 crore, with shares offered in a price band ranging from ₹196 to ₹208 per share. Investors will need to purchase a minimum market lot of 600 shares. The substantial amount being raised indicates robust interest and confidence from the issuer, as well as potentially strong backing from the investor community.

The grey market premium (GMP) for Avience Biomedicals’ IPO stands at ₹40, which signifies a healthy interest from investors prior to its official listing. This indicates positive sentiment in the grey market, suggesting that many retail investors anticipate a favorable listing. While the Kostak rate and Subject to Sauda price are currently unavailable, the consistent GMP reflects a stable demand and a bullish outlook from market traders, who seem to expect a price appreciation post-listing.

This IPO marks a significant moment for Indian investors, particularly those keen on tapping into the SME sector, which has been gaining momentum in recent years. The positive grey market indicators provide an encouraging signal for potential subscribers, highlighting the growing interest in SME issues within the broader IPO landscape. Investors are advised to monitor the subscription data closely as the opening date approaches, as this will provide further insights into market confidence and the potential success of Avience Biomedicals’ share offering.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)